2023
DOI: 10.1093/neuonc/noad236
|View full text |Cite
|
Sign up to set email alerts
|

Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance

Albert E Kim,
Kevin W Lou,
Anita Giobbie-Hurder
et al.

Abstract: Background We recently conducted a phase 2 trial (NCT028865685) evaluating intracranial efficacy of pembrolizumab for brain metastases (BM) of diverse histologies. Our study met its primary efficacy endpoint and illustrates that pembrolizumab exerts promising activity in a select group of patients with BM. Given the importance of aberrant vasculature in mediating immunosuppression, we explored the relationship between checkpoint inhibitor (ICI) efficacy and vascular architecture in the hopes … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 43 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?